Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 3, 2010

Caliper Life Sciences and Sony DADC to Develop Plastic Microfluidic Solutions

  • Caliper Life Sciences and Sony DADC Austria will develop and manufacture plastic consumables for Caliper’s microfluidics products. The agreement combines Sony DADC's Blu-ray Disc manufacturing technology and manufacturing capacity with Caliper's microfluidics expertise and patent portfolio to develop enabling solutions for life science researchers and for diagnostic applications.

    Caliper and Sony have co-developed consumables for the LabChip XT system, Caliper's automated nucleic acid fractionation instrument for next-generation sequencing applications. The LabChip XT removes a key bottleneck in sequencing workflows by replacing gel isolation and purification steps used in size selection, the firm points out. The plastic chips manufactured by Sony DADC allow Caliper to offer a cost-effective and disposable consumable that eliminates cross-contamination potential, which is of key concern for genomics researchers.

    "The exacting requirements for fragment size control in next-gen sequencing are best addressed with Caliper's patented microfluidics technology, while the scale of the opportunity created an opportunity for outsourced manufacturing and the transition to plastic chip format," says Kevin Hrusovsky, president and CEO of Caliper Life Sciences.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »